glp 1 agonist lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk Eli Lilly's orforglipron: a new

doi: 10.3389/fimmu.2021.694217 Summary Keywords gut microbiota, ICU-acquired weakness, ketone bodies, ketogenic diet, sepsis-related acquired weakness Citation Miao Y, Xie L, Chen S, Zhang X, Liu W and Xie P (2024) Ketogenic diet in treating sepsis-related acquired weakness: is it friend or foe

T n ngn nga t bo gan cht do thiu ht Glutathione

Research Highlights VAT Reduction: Tesamorelin significantly reduces visceral adipose tissue (~1520%) in HIV-associated lipodystrophy, with effects maintained over 52 weeks in continuous users

Additionally, human clinical trials highlighted that in a fraction of FMT recipients, particularly melanoma patients who earlier responded to ICI treatment but later developed ICI-resistance, FMT restored the ICI non-responsiveness (266, 267)